Financial Data and Key Metrics Changes - For Q1 2025, the company reported GAAP net income of approximately $9.3 million or $0.17 per common share, with distributable earnings of approximately $7.2 million or $0.13 per common share [11] - The total outstanding borrowings were reduced by $228 million to $946 million, resulting in a net debt to equity ratio of 1.2 times, down from 1.9 times at the end of Q1 2024 [7][12] - The company's liquidity position increased to $147 million as of May 2, 2025, representing a 15% increase since December 31, 2024 [7] Business Line Data and Key Metrics Changes - The company collected $37 million in repayments across nine loans, double the amount from the previous quarter, marking the highest percentage of repayments in the company's history [6][12] - The office loan portfolio was reduced by 25% since March 31, 2024, decreasing the total outstanding balance to $585 million [8] Market Data and Key Metrics Changes - The company maintained stable credit quality with no new risk-rated four or five loans in Q1 2025, and the book value per share remained consistent at $9.88 [11][12] - The CECL reserve declined to $140 million, approximately 9.9% of the total outstanding principal balance of loans held for investment [15] Company Strategy and Development Direction - The strategic goal is to better demonstrate book value, with plans to selectively originate new loans, buy back common shares, repay debt, and fund other strategic initiatives [9][10] - The company aims to leverage its strengthened balance sheet to navigate uncertain markets and enhance shareholder value [10][19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges in the office market, particularly in Chicago, and indicated that the current reserve levels are reflective of the asset's risk [24][25] - The company expects to see a measured cadence of resolutions and repayments, but acknowledges the unpredictability of the market [27][28] Other Important Information - A regular cash dividend of $0.15 per common share was declared for Q2 2025, with an annualized dividend yield of over 14% based on the current stock price [16] - The company has a $50 million buyback authorization in place through July 2025, which is being evaluated as part of capital allocation choices [37] Q&A Session Summary Question: Update on the Chicago office loan - Management noted that while the asset has positive leasing momentum, the overall market dynamics have negatively impacted its valuation, leading to a conservative reserve approach [24][25] Question: Anticipated cadence for resolving non-performing loans - Management indicated that predicting the cadence is difficult due to market volatility, but they are prepared to accelerate resolutions when appropriate [27][28] Question: Plans for regrowing the loan portfolio - Management emphasized a selective approach to new lending opportunities, waiting for market stabilization before making significant moves [32][35] Question: Buyback authorization and capital allocation - Management confirmed a $50 million buyback authorization is in place and is being considered as part of their capital allocation strategy [37] Question: Update on the Life Science Boston project - Management acknowledged challenges in the Life Science market and indicated ongoing discussions with the sponsor, with a cautious reserve approach [40][41] Question: Clarification on strategic initiatives - Management clarified that strategic initiatives include evaluating share buybacks and new investments, particularly in light of recent acquisitions [42][45]

Financial Data and Key Metrics Changes - For Q1 2025, the company reported net income of $0.70 per diluted share, a significant improvement from a net loss of $0.83 per diluted share in Q1 2024 [5] - Interest income increased by $23.6 million to $22 million in Q1 2025, compared to a net loss of $1.6 million in Q1 2024, driven by higher rates [6] - Earnings available for distribution rose to $0.41 per diluted common share in Q1 2025 from negative $0.46 per diluted share in the same period of 2024 [6] - Cash available for distribution was $0.45 per diluted common share in Q1 2025, down from $0.60 per diluted common share in Q1 2024 [6] - Book value per share increased by 1.47% from Q4 2024 to $17.22 per diluted common share, primarily due to unrealized gains on preferred stock investments [7] Business Line Data and Key Metrics Changes - The portfolio consists of 85 investments with a total outstanding balance of $1.2 billion, allocated as follows: 49.4% multifamily, 31.9% life sciences, 15.6% single-family rental, 1.6% storage, 0.9% specialty manufacturing, and 0.6% marina [8] - The assets collateralizing investments are 75.2% stabilized with a loan-to-value ratio of 58.7% and a weighted average debt service coverage ratio (DSCR) of 1.46 times [9] Market Data and Key Metrics Changes - In the life sciences sector, lab leasing remains challenging due to tariff and NIH funding uncertainties, but there are positive developments in specific projects like the Alewife project, which is negotiating leases for two-thirds of the space [12][13] - The residential sector saw strong demand with over 138,000 units absorbed in Q1 2025, indicating a robust rental market despite affordability challenges [14] - The company has observed positive new lease growth across 40% of its rental portfolio, up from just 5% in Q4 2024 [15] Company Strategy and Development Direction - The company aims to focus on the residential sector and is actively pursuing self-storage development opportunities, expecting yields between 8.1% to 8.5% [15][16] - There is a strategic emphasis on underwriting shorter-term senior opportunities to stabilize assets and facilitate lease-up in the residential front [31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the residential sector's performance over the next two to three years, despite short-term macroeconomic uncertainties [22] - The company remains active in its key verticals and anticipates continued growth in the coming quarters [17] Other Important Information - The company paid a regular dividend of $0.50 per share in Q1 2025 and has declared the same for Q2 2025, with the dividend being 0.9 times covered by cash available for distribution [7] Q&A Session Summary Question: Can you comment on the credit side and notable credit loss provision? - Management indicated that a weighted average base case and downside scenario for CECL reserve was implemented, along with a proactive reserve for a private preferred asset [19][20] Question: What percentage leased will the Alewife project be? - The project is expected to be two-thirds leased, resulting in a debt yield of nearly 11% from those leases [24] Question: What are the interesting opportunities in the current environment? - Management plans to focus on residential space, preferreds, and ramping up CMBS B pieces, particularly in shorter-term stretch senior opportunities [31]